Fig. 5

Ipilimumab does not block B7-CTLA-4 interaction in vivo. a Diagram of experimental design. b Representative data showing the phenotype of CD11b⁺CD11c^high DC analyzed for B7 expression. c Representative histograms depicting the levels of mB7-1 on DC from mice that received control hIgG-Fc, L3D10 or Ipilimumab. Data in the top panel show antibody effect in homozygous human CTLA4 knock-in mice (Ctla4^h/h), while that in the bottom panel show antibody effect in the heterozygous mice (Ctla4^h/m). d As in c, except that expression of mB7-2 is shown. Data shown in c and d are representative of those from three mice per group and have been repeated once. e In human CTLA4 homozygous mice, L3D10 but not Ipilimumab-induced upregulation of mB7-1 (left panel) and mB7-2 (right panel). Data shown (mean ± S.E.M.) are summarized from two experiments involving a total of six mice per group. f As in e, except that heterozygous mice are used. Neither L3D10 nor Ipilimumab blocks B7-CTLA-4 interaction in mice that co-dominantly express both mouse and human Ctla4 genes. Statistical significance was determined using Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. n.s., not significant